Correction MAR-label: CESSATECH PUBLISHES OFFERING MEMORANDUM IN CONNECTION WITH 80% GUARANTEED RIGHTS ISSUE

København, Denmark, October 20, 2022 – Cessatech A/S (“Cessatech” or the “Company”) today released the Offering Memorandum in connection with the upcoming rights issue (the “Rights Issue” or the “Offering”). The Offering Memorandum, the application form and other information about the Offering is available on the Company’s website, www.cessatech.com, under fillings and reports. One (1) existing share in Cessatech held on the record date of October 25, 2022, entitles to one (1) Unit Right. Four (4) Unit Rights entitles to subscription of one (1) Unit. One (1) Unit comprise of six (6) new shares and three (3) warrants of series TO2 free of charge. The subscription price is DKK 12 per unit, corresponding to DKK 2 per share. The Subscription period of the Rights Issue runs from October 27 up until November 9, 2022, both days included.

Advisors
Translution Capital acts as financial advisors to the Company in connection with the Offering. Nordic Issuing is the Company’s issuing agent whereas Elmann Law Firm is the Company’s legal advisor in connection with the Offering.

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development.